About thermogenesis - THMO
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
THMO At a Glance
ThermoGenesis Holdings, Inc.
2890 Kilgore Road
Rancho Cordova, California 95670
| Phone | 1-916-858-5100 | Revenue | 9.45M | |
| Industry | Medical Specialties | Net Income | -17,975,000.00 | |
| Sector | Health Technology | Employees | 25 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
THMO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.151 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.619 |
| Enterprise Value to Sales | 0.93 |
| Total Debt to Enterprise Value | 1.284 |
THMO Efficiency
| Revenue/Employee | 377,800.00 |
| Income Per Employee | -719,000.00 |
| Receivables Turnover | 9.953 |
| Total Asset Turnover | 0.617 |
THMO Liquidity
| Current Ratio | 0.44 |
| Quick Ratio | 0.321 |
| Cash Ratio | 0.17 |
THMO Profitability
| Gross Margin | 8.629 |
| Operating Margin | -69.603 |
| Pretax Margin | -200.307 |
| Net Margin | -190.312 |
| Return on Assets | -117.415 |
| Return on Equity | -1,367.44 |
| Return on Total Capital | -186.947 |
| Return on Invested Capital | -392.682 |
THMO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 117.337 |
| Total Debt to Total Assets | 100.445 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 30.161 |